Pipeline
MBT-002
Botulinum toxin is a highly potent biological agent that precisely modulates neurotransmission and has played a critical role across both aesthetic and therapeutic applications. However, conventional formulations have continued to face limitations in predictability, duration of effect, and safety due to constraints in their production methods and molecular structures.
MBT-002 is a next-generation recombinant botulinum toxin candidate designed to address these challenges. Through E. coli–based recombinant production and precise protein engineering, MBT-002 achieves rapid onset of action, prolonged efficacy, and an improved safety profile simultaneously. As a result, it delivers more reliable and high-quality outcomes compared to existing botulinum toxin products.
With MBT-002, MVRIX aims to establish a new benchmark for botulinum toxin therapies that extend beyond aesthetic use into therapeutic indications, offering differentiated and clinically meaningful treatment options.
Challenges that Ex-vivo CAR-T face
Long and costly treatment
Complex development requiring dedicated facilities
Patient risks
(lymphodepletion and other side effects)
Ex vivo CAR-T involves isolating a patient’s T cells, inserting the CAR gene, and expanding the modified cells outside the body before reinfusion. This process requires dedicated manufacturing facilities and long development timelines, resulting in high treatment costs and limited accessibility that place significant physical and financial burdens on patients.
In vivo CAR-T
Short treatment time and 1/10 the cost
Simple process, customization
Reduced risk (Combination therapy and repeat dosing)
In vivo CAR-T therapy generates CAR genes directly inside the body, enabling true off-the-shelf treatment.
This approach shortens treatment time and reduces costs, allowing patients to receive care at local hospitals without the need for specialized facilities. It also lowers patient burden, making combination therapy and repeated dosing more feasible.
Improvement strategy of MBT-002
Enhanced duration of Effect
By strengthening interactions within intracellular protein degradation pathways, we improve protein homeostasis and stability. This results in in a significant extension of the duration of therapeutic effect.
Accelerated onset of action
By increasing binding affinity to toxin is enhanced. As a result, a faster onset of action is achieved following administration.
Improved safety profile
Enhanced binding affinity to toxin receptors promotes target-site-focused activity, thereby improving the overall safety profile..
Challenges that Ex-vivo CAR-T face
Long and costly treatment
Complex development requiring dedicated facilities
Patient risks
(lymphodepletion and other side effects)
Ex vivo CAR-T involves isolating a patient’s T cells, inserting the CAR gene, and expanding the modified cells outside the body before reinfusion. This process requires dedicated manufacturing facilities and long development timelines, resulting in high treatment costs and limited accessibility that place significant physical and financial burdens on patients.
In vivo CAR-T
Short treatment time and 1/10 the cost
Simple process, customization
Reduced risk (Combination therapy and repeat dosing)
In vivo CAR-T therapy generates CAR genes directly inside the body, enabling true off-the-shelf treatment.
This approach shortens treatment time and reduces costs, allowing patients to receive care at local hospitals without the need for specialized facilities. It also lowers patient burden, making combination therapy and repeated dosing more feasible.
MBT-002 results
Enhanced safety profile
MBT-002 demonstrates 100% purity
Extended durability
Up to twofold longer duration compared to currently marketed toxins
Accelerated onset
Demonstrates an onset rate comparable to fast-acting type E toxins